Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue 5, 2004, Pages 797-803

  King, Anna ^a   Phillips, Ians ^a   Kaniga, Koné ^b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b THERAVANCE INC   (United States)

Author keywords

Enterococci; Glycopeptides; Staphylococcus aureus; Streptococci; Susceptibility testing

Indexed keywords

AGAR; AMPICILLIN; ANTIINFECTIVE AGENT; DALFOPRISTIN PLUS QUINUPRISTIN; LINEZOLID; MOXIFLOXACIN; OXACILLIN; PENICILLIN G; TEICOPLANIN; TELAVANCIN; UNCLASSIFIED DRUG; VANCOMYCIN;

AEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; CLINICAL LABORATORY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; DILUTION; DRUG STRUCTURE; ENTEROCOCCUS; GRAM POSITIVE BACTERIUM; IN VITRO SELECTION; LACTOBACILLUS; METHODOLOGY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATIENT CARE; PRACTICE GUIDELINE; SPECIES DIFFERENCE; STRUCTURE ANALYSIS; UNITED KINGDOM;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CULTURE MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 2442674119     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh156     Document Type: Article

References (27)

1. Uttley, A. H., George, R. C., Naidoo, J. et al. (1989). High-level vancomycin-resistant enterococci causing hospital infection. Epidemiology and Infection 103, 173-81.
2. Bugg, T. D. H., Wright, G. D., Dutka-Malen, S. S. et al. (1991). Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA. Biochemistry 30, 10408-15.
3. Leclerq, R. & Courvalin, P. (1997). Resistance to glycopeptides in enterococci. Clinical Infectious Diseases 24, 545-56.
4. Panlilio, A. L., Culver, D. H., Gaynes, R. P. et al. (1992). Methicillin-resistant S. aureus in U. S. hospitals, 1975-1991. Infection Control Hospital Epidemiology 13, 582-6.
5. Steinberg, J. P., Clark, C. C. & Hackman, B. O. (1996). Nosocomial and community-acquired Staphylococcus aureus bacteremias from 1980-1993: impact of intravascular devices and methicillin resistance. Clinical Infectious Diseases 23, 255-9.
6. Velduijzen, I., Bronzwaer, S., Degener, J. et al. (2000). European Antimicrobial Resistance Surveillance System (EARSS): susceptibility testing of invasive Staphylococcus aureus. Surveillance report. Eurosurveillance Monthly 5, 34-6.
7. Lowy, F. (1998). Staphylococcus aureus infections. New England Journal of Medicine 339, 520-32.
8. Sierieradzki, K., Roberts, R. B., Haber, S. W. et al. (1999). The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. New England Journal of Medicine 340, 517-32.
9. Smith, T. L., Pearson, M. L., Wilcox, K. R. et al. (1999). Emergence of vancomycin resistance in Staphylococcus aureus. New England Journal of Medicine 340, 493-501.
10. Valdvogel, F A. (1999). New resistance in Staphylococcus aureus (editorial). New England Journal of Medicine 340, 556-7.
11. Hiramatsu, K., Hanaki, H., Ino, T. et al. (1997). Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. Journal of Antimicrobial Chemotherapy 40, 135-6.
12. Hiramatsu, K. (1998). The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. American Journal of Medicine 104, 7S-10S.
13. Bell, J. M., Turnidge, J. D. & SENTRY APAC Participants. (2002). High prevalence of oxacillin-resistant Staphylococcus aureus isolates from hospitalized patients in Asia-Pacific and South Africa: results from SENTRY Antimicrobial Surveillance Program, 1998-1999. Antimicrobial Agents and Chemotherapy 46, 879-81.
14. Diekema, D., Pfaller, M. A., Turnidge, J. et al. (2000). Genetic relatedness of multidrug-resistant, methicillin (oxacillin)-resistant Staphylococcus aureus bloodstream isolates from SENTRY antimicrobial resistance surveillance centers worldwide, 1988. Microbial Drug Resistance 6, 213-21.
15. Sievert, D. M., Boulton, M. L., Stoltman, G. et al. (2002). Staphylococcus aureus resistant to vancomcyin - United States, 2002. Morbidity and Mortality Weekly Report 51, 565-7.
16. Chang, S., Sievert, D. M., Hageman, J. C. et al. (2003). Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. New England Journal of Medicine 348, 1342-47.
17. Baquero, F. (1995). Pneumococcal resistance to β-lactam antibiotics: a global geographic overview. Microbial Drug Resistance 1, 115-20.
18. McCormick, A. W., Whitney, C. G., Farley, M. M. et al. (2003). Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the Unites States. Nature Medicine 9, 424-30.
19. Pace, J. L., Krause, K., Johnston, D. et al. (2003). In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 47, 3602-4.
20. Debabov, D. V., Pace, J., Nodwell, M. et al. (2003). TD-6424, a novel rapidly bactericidal concentration-dependent antibiotic, acts through a unique dual mode of action. In Programs and Abstracts of the Forty-Third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Abstract C1-1809, p. 96. American Society for Microbiology, Washington, DC, USA.
21. Barriere, S., Shaw, J. P., Seroogy, J. et al. (2003). Pharmacokinetic disposition and serum bactericidal activity following i.v. infusion of single and multiple ascending doses of TD-6424 in healthy male subjects. Clinical Microbiology and Infection 9, Suppl. 1, 288.
22. National Committee for Clinical Laboratory Standards. (2000). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Fifth Edition: Approved Standard M7-A5. NCCLS, Villanova, PA, USA.
23. European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). (2000). Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by agar dilution. Clinical Microbiology and Infection 6, 509-15.
24. Andrews, J. M. (2001). Determination of minimum inhibitory concentrations. Journal of Antimicrobial Chemotherapy 48, Suppl. S1, 2-16.
25. National Committee for Clinical Laboratory Standards. (2003). Performance Standards for Antimicrobial Susceptibility Testing - Thirteenth Informational Supplement, 22, No 1. M100-S13. NCCLS, Villanova, PA, USA.
26. MacGowan, A. P. & Wise, R. (2001). Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. Journal of Antimicrobial Chemotherapy 48, Suppl. S1, 17-28.
27. Kobayashi, N., Wu, H., Kojima, K. et al. (1994). Detection of mecA, femA and femB genes in clinical strains of staphylococci using polymerase chain reaction. Epidemiology and Infection 113, 259-66.